Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.51 |
| ▸ | CA2 | P00918 | 5/20 | 0.51 |
| ▸ | CA9 | Q16790 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12518632 | 0.83 | CA12 (0.55) | CA12CA1CA2CA9MAPT | |
| SCHEMBL1571346 | 0.83 | CA12 (0.50) | CA12CA1CA2CA9MAPT | |
| SCHEMBL10086759 | 0.83 | CA12 (0.56) | CA12CA1CA2CA9LMNA | |
| SCHEMBL6183257 | 0.82 | CA12 (0.66) | CA12CA1CA2CA9MAPT | |
| SCHEMBL30300884 | 0.82 | SCN9A (0.39) | CA12CA1CA2CA9MAPT | |
| SCHEMBL30301089 | 0.81 | CA12 (0.55) | CA12CA1CA2CA9GAA | |
| SCHEMBL16450757 | 0.80 | CA12 (0.64) | CA12CA1CA2CA9GAA | |
| SCHEMBL25718483 | 0.80 | CA12 (0.56) | CA12CA1CA2CA9MAPT | |
| SCHEMBL5418888 | 0.79 | MEN1 (0.55) | CA12CA1CA2CA9MAPT | |
| SCHEMBL29379386 | 0.79 | MEN1 (0.55) | CA12CA1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4392409-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023027966-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | CA12 4586/4885CA1 4305/4885CA2 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.